Phase 4
Completed N=206
Efficacy of Liposomal Bupivacaine Versus 0.25% Bupivacaine for Laparoscopic Urologic Surgery
Pain, Postoperative
Source: ClinicalTrials.gov NCT02222129 ↗
Enrolled (actual)
206
Serious AEs
0.0%
Results posted
Apr 2015
Primary outcomePrimary: Total Opioid Consumption Measured in Intravenous Morphine Equivalents During the Postoperative Hospital Stay — 17.3; 15 mg (morphine equivalents) — p=0.39
Summary
A prospective, randomized comparison of bupivacaine to liposomal bupivacaine given by local injection at all the wound sites in patients undergoing robotic-assisted or laparoscopic urologic surgeries in an effort to determine which method reduced postoperative opioid use the most.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Opioid Consumption Measured in Intravenous Morphine Equivalents During the Postoperative Hospital Stay |
17.3; 15 | 0.39 |
| SECONDARY Visual Analog Pain Scores. |
— | — |
| SECONDARY Length of Hospital Stay. |
— | — |
| SECONDARY Time to First Opioid Use. |
— | — |
Eligibility Criteria
Inclusion Criteria
- At least 18-years-old, undergoing laparoscopic urologic surgery.
Exclusion Criteria
- Pregnant and/or nursing mothers.
- Allergy to bupivacaine.
Data sourced from ClinicalTrials.gov (NCT02222129). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.